Literature DB >> 33139990

Clinical value of dual-phase F-18 sodium fluoride PET/CT for diagnosing bone metastasis in cancer patients with solitary bone lesion.

Jeong Won Lee1, Yong-Jin Park2, Youn Soo Jeon3, Ki Hong Kim3, Jong Eun Lee4, Sung Hoon Hong4, Sang Mi Lee5, Su Jin Jang6.   

Abstract

BACKGROUND: The present study aimed to investigate whether dual-phase F-18 sodium-fluoride (NaF) positron emission tomography/computed tomography (PET/CT) could improve the diagnostic accuracy of detecting bone metastasis in cancer patients with a solitary bone lesion compared to conventional F-18 NaF PET/CT.
METHODS: We retrospectively enrolled 113 cancer patients who underwent dual-phase F-18 NaF PET/CT for the differential diagnosis of a solitary bone lesion seen on bone scintigraphy. According to the dual-phase PET/CT protocol, an early-phase scan was acquired immediately after radiotracer injection and a conventional F-18 NaF PET/CT scan was performed. The diagnostic abilities of the visual analysis of conventional and dual-phase PET/CT scans and two quantitative parameters (lesion-to-blood pool uptake ratio on early-phase scan and lesion-to-bone uptake ratio on conventional scan) for detecting bone metastasis were compared. The final diagnosis of bone metastasis was made by histopathological confirmation or follow-up imaging studies.
RESULTS: A metastatic bone lesion was diagnosed in 28 patients (24.8%). The sensitivity, specificity, and accuracy were 100.0%, 70.6%, and 77.9%, respectively, for visual analysis of conventional F-18 NaF PET/CT, 92.9%, 42.4%, 54.9%, respectively, for lesion-to-bone uptake ratio, 96.4%, 88.2%, and 90.3%, respectively, for visual analysis of dual-phase PET/CT, and 92.9%, 81.2%, and 83.2%, respectively, for lesion-to-blood pool uptake ratio. Visual analysis of dual-phase PET/CT was shown to have the highest area under the receiver operating characteristic curve value (0.923; 95% CI, 0.858-0.965) among all parameters.
CONCLUSIONS: Dual-phase F-18 NaF PET/CT showed a high diagnostic ability for detecting bone metastasis with improved specificity and accuracy compared to conventional F-18 NaF PET/CT in cancer patients. Dual-phase F-18 NaF PET/CT might help diagnose bone metastasis in patients with malignancies who were shown to have a solitary bone lesion on bone scintigraphy. 2020 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Bone; F-18 Sodium-fluoride (NaF); diagnosis; metastasis; positron emission tomography (PET)

Year:  2020        PMID: 33139990      PMCID: PMC7547267          DOI: 10.21037/qims-20-607

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  40 in total

1.  [Magnetic resonance tomography of the bone marrow in cancer patients with a solitary area of increased uptake in the bone scintigram].

Authors:  K Smolarz; M Jungehülsing; B Krug; A Linden; U J Göhring; H Schicha
Journal:  Nuklearmedizin       Date:  1990-12       Impact factor: 1.379

2.  Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.

Authors:  Mads H Poulsen; Henrik Petersen; Poul F Høilund-Carlsen; Jørn S Jakobsen; Oke Gerke; Jens Karstoft; Signe I Steffansen; Steen Walter
Journal:  BJU Int       Date:  2014-05-22       Impact factor: 5.588

3.  Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis.

Authors:  Chen-Tian Shen; Zhong-Ling Qiu; Ting-Ting Han; Quan-Yong Luo
Journal:  Clin Nucl Med       Date:  2015-02       Impact factor: 7.794

4.  Earlier Phases of Bone Scintigraphy Can Better Delineate the Extent of Soft Tissue Involvement of Bone Metastasis.

Authors:  Derya Çayir; Mehmet Bozkurt; Salih Sinan Gültekin; Alper Özgür Karaçalioğlu
Journal:  Clin Nucl Med       Date:  2018-11       Impact factor: 7.794

5.  Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma.

Authors:  Wouter A M Broos; Friso M van der Zant; Maurits Wondergem; Remco J J Knol
Journal:  Nucl Med Commun       Date:  2018-04       Impact factor: 1.690

6.  Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT).

Authors:  Hervé Nyangoga; Philippe Mercier; Hélène Libouban; Michel Félix Baslé; Daniel Chappard
Journal:  PLoS One       Date:  2011-03-28       Impact factor: 3.240

7.  18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract.

Authors:  Mi Ra Kim; Jong-Lyel Roh; Jae Seung Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Oral Oncol       Date:  2007-03-12       Impact factor: 5.337

8.  Clinical significance of solitary rib lesions in patients with extraskeletal malignancy.

Authors:  S S Tumeh; G Beadle; W D Kaplan
Journal:  J Nucl Med       Date:  1985-10       Impact factor: 10.057

Review 9.  Site specific measurements of bone formation using [18F] sodium fluoride PET/CT.

Authors:  Glen M Blake; Tanuj Puri; Musib Siddique; Michelle L Frost; Amelia E B Moore; Ignac Fogelman
Journal:  Quant Imaging Med Surg       Date:  2018-02

10.  First experience with early dynamic (18)F-NaF-PET/CT in patients with chronic osteomyelitis.

Authors:  Martin Freesmeyer; Franz F Stecker; Jan-Henning Schierz; Gunther O Hofmann; Thomas Winkens
Journal:  Ann Nucl Med       Date:  2014-01-29       Impact factor: 2.668

View more
  2 in total

1.  Clinical utility of F-18 sodium fluoride PET/CT for estimating disease activity in patients with rheumatoid arthritis.

Authors:  Hee Jin Park; Sung Hae Chang; Jeong Won Lee; Sang Mi Lee
Journal:  Quant Imaging Med Surg       Date:  2021-04

2.  Comparison of the Relative Diagnostic Performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT for the Detection of Bone Metastasis in Patients With Different Cancers.

Authors:  Junhao Wu; Yingwei Wang; Taiping Liao; Zijuan Rao; Weidong Gong; Lei Ou; Yue Chen; Chunyin Zhang
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.